Anthem Biosciences IPO booked nearly 10 times so far on Day 3; GMP indicates 27% listing premium

The initial public offering (IPO) of Bengaluru-based Anthem Biosciences has garnered healthy investor interest, with the subscription period set to close on Wednesday, July 16.

The IPO was subscribed 9.78 times so far on the third and final day of the bidding process.

The non institutional investors (NIIs) led the demand, subscribing to 25.76 times the allotted portion, while the qualified institutional buyers had subscribed to 8.55 times their allotted quota. Meanwhile, the retail investors had subscribed by 3.68 times and the employees quota witnessed 4.42 times subscriptions.

Anthem Biosciences IPO GMP today

The decent response in the subscription phase is further supported by a healthy grey market premium (GMP), which is currently around ₹153.

This represents a premium of 27% over the issue price, indicating strong investor confidence and the potential for a favourable listing.

However, it is important to note that grey market premiums are just an indicator of how the company's shares are stacked up in the unlisted market and are subject to change rapidly.

Anthem Biosciences IPO details

Anthem Biosciences is selling its shares in a fixed price band of ₹540 to ₹570. At the upper price band, the company’s valuation stands at over ₹31,800 crore.

Anthem Biosciences is raising ₹3,395 crore through an initial share sale, which comprises of entirely an offer-for-sale by existing shareholders including investors Viridity Tone, and Portsmouth Technologies.

The company will not receive any from the public issue. All the funds, excluding offer expenses, will go to selling shareholders.

Ahead of the issue launch, the company had already mopped up ₹1,016 crore from 60 institutional investors via its anchor book.

Marquee names like Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, Optimix Wholesale Global Emerging Markets Share Trust, PineBridge Global Funds, and Societe Generale bought shares of the pharma company via anchor book.

Incorporated in 2006, Anthem Biosciences is a full-service CRDMO offering end-to-end solutions to pharma and biotech firms, covering drug development from early research to commercial manufacturing through an
integrated model that simplifies processes and reduces compliance hassles.

JM Financial is the book-running lead manager of the Anthem Biosciences IPO, while Kfin Technologies is the registrar.

The allotment for the Anthem Biosciences IPO is expected to be finalised on July 17, while the shares will be listing on BSE, NSE with a tentative listing date fixed as July 21, 2025.